Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton May 21, 2021 12:50pm

172 Views

Post# 33248414

RE:RE:RE:RE:RE:RE:Markets

Mugs
Not tracking this "I can only assume their patent life is much greater than the 5 years remaining for OTENA"
Otenal loses US exclusivity in 2032. slide 20 https://antibethera.com/wp-content/uploads/2021/04/Antibe-Corporate-Presentation-April-2021.pdf

BTW funny story on SAVA - had 3K shares / $9 avg pps and bought right after the posiitve earlier PH2 study only to watch the stock tank to $3 as the ph2b studies were not solid - ended up being a testing issue with the lab or something (I sold a few weeks after the drop) and then watch the stock jump as it did... Als is a larger market potential but highly risky as no drugs to date have impressed,

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload